Source: MVS Noticias

The company Sanofi Aventis filed a complaint for counterfeiting of the Plaquenil product.

The Federal Commission for the Protection against Sanitary Risks (Cofepris) issued a health alert for the counterfeiting of the drug hydroxychloroquine, marketed under the name Plaquenil.

In a statement, he explained that the company Sanofi Aventis filed a complaint for the falsification of the product Plaquenil in its presentation of 200 milligram tablets and warned that this product does not contain the active ingredient hydroxychloroquine , instead microcrystalline cellulose was identified , and the box There are differences in the printing of the price, the font used in the texts and the color.

Related:

Mexico to administer hydroxychloroquine to 20,000

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis

How a False Hydroxychloroquine Narrative Was Created. “Dangerous” When Used for Covid-19

National Cancer Instititute: List of Active Clinical Trials Using Hydroxychloroquine for Cancer

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Facebook Suspends Craig Kelly For Posts Citing Medical Professionals

“The effect of censoring debate on these early treatments could have possibly been responsible for the death of hundreds of thousands of people.
So, where we should have been having more open debate and more free debate, shutting down debate is likely to have killed people. Not just one or two people, but probably hundreds of thousands. This is why throughout the last 250 years people have said free speech is so important. This is why people have said, ‘I may not agree with what you say but I’ll fight to my death your right to say it.’”

Read More »